• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Accounting Officer Abate Kristin sold $952 worth of shares (238 units at $4.00), decreasing direct ownership by 2% to 9,475 units (SEC Form 4)

    7/23/25 5:18:34 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Abate Kristin

    (Last) (First) (Middle)
    C/O KARYOPHARM THERAPEUTICS INC.
    85 WELLS AVENUE

    (Street)
    NEWTON MA 02459

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Karyopharm Therapeutics Inc. [ KPTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Accounting Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/22/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/22/2025 S(1) 238 D $4 9,475 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
    /s/Nancy Smith as Attorney-in-Fact for Kristin Abate 07/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KPTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KPTI

    DatePrice TargetRatingAnalyst
    7/16/2025Buy → Neutral
    H.C. Wainwright
    7/11/2025$27.00Buy
    H.C. Wainwright
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    1/10/2022$6.00 → $8.00Market Perform
    SVB Leerink
    More analyst ratings

    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc

    8/11/25 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

    -- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopha

    8/5/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive

    8/1/25 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Development Officer Poulton Stuart sold $835 worth of shares (191 units at $4.37), decreasing direct ownership by 0.70% to 27,223 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    7/30/25 4:56:49 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Abate Kristin sold $952 worth of shares (238 units at $4.00), decreasing direct ownership by 2% to 9,475 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    7/23/25 5:18:34 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Su Zhen

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    5/29/25 4:15:13 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    SEC Filings

    View All

    SEC Form S-8 filed by Karyopharm Therapeutics Inc.

    S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    8/11/25 8:01:42 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Karyopharm Therapeutics Inc.

    10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    8/11/25 7:34:05 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    8/11/25 7:31:35 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Karyopharm Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral

    7/16/25 7:54:08 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Karyopharm Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $27.00

    7/11/25 8:13:36 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Karyopharm Therapeutics with a new price target

    Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00

    1/19/23 7:43:39 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

    NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

    1/2/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

    NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

    12/9/24 8:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

    NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

    11/20/24 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/12/24 3:50:51 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/4/24 11:49:19 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Financials

    Live finance-specific insights

    View All

    Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc

    8/11/25 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

    -- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopha

    8/5/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

    – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns

    5/12/25 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care